Advisory Services Network LLC bought a new stake in Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 34,868 shares of the biopharmaceutical company’s stock, valued at approximately $4,339,000. Celgene Corporation comprises approximately 0.6% of Advisory Services Network LLC’s portfolio, making the stock its 14th largest position.

Several other large investors have also bought and sold shares of the company. SPC Financial Inc. increased its stake in Celgene Corporation by 32.5% in the first quarter. SPC Financial Inc. now owns 6,825 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 1,675 shares during the last quarter. Wright Investors Service Inc. increased its stake in Celgene Corporation by 4.9% in the first quarter. Wright Investors Service Inc. now owns 8,572 shares of the biopharmaceutical company’s stock valued at $1,067,000 after buying an additional 400 shares during the last quarter. Advisor Partners LLC increased its stake in Celgene Corporation by 1.8% in the first quarter. Advisor Partners LLC now owns 12,287 shares of the biopharmaceutical company’s stock valued at $1,529,000 after buying an additional 220 shares during the last quarter. Coconut Grove Bank increased its stake in Celgene Corporation by 10.9% in the first quarter. Coconut Grove Bank now owns 2,665 shares of the biopharmaceutical company’s stock valued at $331,000 after buying an additional 261 shares during the last quarter. Finally, Cadence Bank NA increased its stake in Celgene Corporation by 0.6% in the first quarter. Cadence Bank NA now owns 7,496 shares of the biopharmaceutical company’s stock valued at $933,000 after buying an additional 45 shares during the last quarter. 78.24% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Shares of Celgene Corporation (NASDAQ CELG) opened at 122.36 on Friday. The company has a market cap of $95.54 billion, a price-to-earnings ratio of 45.95 and a beta of 1.82. The stock has a 50 day moving average of $119.11 and a 200 day moving average of $119.63. Celgene Corporation has a 52-week low of $94.42 and a 52-week high of $127.64. Celgene Corporation also was the target of some unusual options trading activity on Friday. Stock investors acquired 1,785 call options on the stock. This is an increase of approximately 104% compared to the average volume of 873 call options.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.21. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3.04 billion. During the same quarter in the previous year, the firm earned $1.32 earnings per share. The company’s revenue for the quarter was up 17.8% on a year-over-year basis. On average, equities research analysts expect that Celgene Corporation will post $7.29 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Advisory Services Network LLC Invests $4.34 Million in Celgene Corporation (CELG)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/06/18/advisory-services-network-llc-invests-4-34-million-in-celgene-corporation-celg.html.

Several research firms have recently commented on CELG. Leerink Swann raised shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $94.42 to $150.00 in a research report on Friday. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub raised shares of Celgene Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Cann reissued a “buy” rating on shares of Celgene Corporation in a research report on Wednesday, June 7th. Finally, Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. Celgene Corporation currently has an average rating of “Buy” and a consensus target price of $139.49.

In other Celgene Corporation news, Director James J. Loughlin sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the transaction, the director now owns 32,169 shares of the company’s stock, valued at $3,988,956. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilla Kaplan sold 14,033 shares of Celgene Corporation stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the transaction, the director now directly owns 73,109 shares in the company, valued at approximately $9,053,087.47. The disclosure for this sale can be found here. Insiders have sold 28,068 shares of company stock worth $3,459,768 in the last ninety days. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.